If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

Dr. Todd Schell's research focuses on defining immune-based therapies for cancer. His interests include evaluating approaches to improve the persistence and function of tumor-reactive T lymphocytes within the tumor microenvironment. These studies have defined how tumor-reactive T-cells behave in distinct types of cancer including those that occur in the brain, pancreas, prostate and skin. Emphasis is placed on the use of adoptive T-cell therapies as well as defining how existing immune-based therapies currently used in cancer patients can be further improved.

Recent studies from the Schell laboratory highlight how antibody-based therapies targeting CD40 or PD-1 can be improved through combination with existing approaches such as radiation or common medications such as beta-blockers. Through collaborations with clinical investigators, translational studies focus on identification of patient characteristics that are associated with durable clinical responses to immune-based therapies, particularly for metastatic melanoma.

In addition to his research, Dr. Schell is the faculty director of Penn State College of Medicine's Flow Cytometry Core Facility.

Education/Academic qualification

Postdoctoral Training, College of Medicine (Hershey)

… → 1999

PhD, West Viginia University School of Medicine

… → 1995

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 15 Similar Profiles
T-Lymphocytes Medicine & Life Sciences
Epitopes Medicine & Life Sciences
Viral Tumor Antigens Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Neoplasm Antigens Medicine & Life Sciences
Transgenic Mice Medicine & Life Sciences
Simian virus 40 Medicine & Life Sciences
Cytotoxic T-Lymphocytes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1978 2015

Immunity
T-Lymphocytes
Psychological Stress
Neoplasms
Immune System

BIOLOGY OF SV40-SPECIFIC TRANSPLANTATION ANTIGEN

Schell, T. & Tevethia, S. S.

National Institutes of Health

6/1/7811/30/15

Project: Research project

Polyomavirus Transforming Antigens
Immunotherapy
T-Lymphocytes
Neoplasms
Viral Tumor Antigens

Research Output 1994 2019

  • 1275 Citations
  • 20 h-Index
  • 64 Article
  • 3 Review article
  • 2 Comment/debate
  • 1 Letter
1 Citation (Scopus)

Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer

Bazewicz, C. G., Dinavahi, S. S., Schell, T. & Robertson, G., Jan 1 2019, In : Immunology. 156, 1, p. 47-55 9 p.

Research output: Contribution to journalReview article

Aldehyde Dehydrogenase
Regulatory T-Lymphocytes
Immunity
Neoplasms
Immune Tolerance
1 Citation (Scopus)
Open Access
Acute Myeloid Leukemia
T-Lymphocytes
Leukemia
Transcription Factors
Induction Chemotherapy
1 Citation (Scopus)

Increased circulating microparticles in streptozotocin-induced diabetes propagate inflammation contributing to microvascular dysfunction

Feng, Q., Stork, C. J., Xu, S., Yuan, D., Xia, X., LaPenna, K. B., Guo, G., Sun, H., Xu, L., Siedlecki, C., Brundage, K. M., Sheaffer, N., Schell, T. & He, P., Feb 1 2019, In : Journal of Physiology. 597, 3, p. 781-798 18 p.

Research output: Contribution to journalArticle

Experimental Diabetes Mellitus
Inflammation
Microvessels
Phosphatidylserines
Blood Vessels

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity

Kokolus, K. M., Haley, J. S., Koubek, E. J., Gowda, R., Dinavahi, S. S., Sharma, A., Claxton, D., Helm, K., Drabick, J., Robertson, G., Neighbors, J., Hohl, R. & Schell, T., Feb 1 2019, In : OncoImmunology. 8, 2, e1539614.

Research output: Contribution to journalArticle

Biological Products
Immunity
Melanoma
Immunotherapy
Neoplasms
12 Citations (Scopus)

Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice

Kokolus, K. M., Zhang, Y., Sivik, J. M., Schmeck, C., Zhu, J., Repasky, E. A., Drabick, J. & Schell, T., Mar 4 2018, In : OncoImmunology. 7, 3, e1405205.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Adrenergic Receptors
Survival
Interleukin-2